The prognostic significance of heparanase expression in metastatic melanoma

Oncotarget

Volumn 7, Issue 46, 2016, Pages 74678-74685

  Vornicova, Olga ^a   Boyango, Ilanit ^b   Feld, Sari ^b   Naroditsky, Inna ^c   Kazarin, Olga ^a   Zohar, Yaniv ^c   Tiram, Yariv ^b   Ilan, Neta ^b   Ben Izhak, Ofer ^c   Vlodavsky, Israel ^b   Bar Sela, Gil ^a  

^a Division of Oncology   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c NONE   (Israel)

Author keywords

Heparanase; Heparanase 2; Melanoma; Metastasis; Survival

Indexed keywords

HEPARANASE; HEPARANASE 2; PARAFFIN; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; BIOLOGICAL MARKER;

ARTICLE; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; SKIN METASTASIS; SURVIVAL RATE; SURVIVAL TIME; ADULT; AGED; GENE EXPRESSION; GENETICS; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; FEMALE; GENE EXPRESSION; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84996848923     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12492     Document Type: Article

References (38)

1. Parish CR, Freeman C and Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001; 1471(3):M99-108.
2. Vlodavsky I and Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001; 108(3):341-347.
3. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N and Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010; 277(19):3890-3903.
4. Ilan N, Elkin M and Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Intl J Biochem & Cell Biol. 2006; 38(12):2018-2039.
5. Vreys V and David G. Mammalian heparanase: what is the message? J Cell Mol Med. 2007; 11(3):427-452.
6. Hammond E, Khurana A, Shridhar V and Dredge K. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol. 2014; 4:195.
7. Rivara S, Milazzo FM and Giannini G. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem. 2016; 8 (6):647-680.
8. Wang X, Wen W, Wu H, Chen Y, Ren G and Guo W. Heparanase expression correlates with poor survival in oral mucosal melanoma. Med Oncol. 2013; 30(3):633.
9. Xu S, Yang Z, Zhang J, Jiang Y, Chen Y, Li H, Liu X, Xu D, Yang Y, Zhang Y, Li D and Xia J. Increased levels of beta-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2. DNA Cell Biol. 2015; 34(1):69-77.
10. Edovitsky E, Elkin M, Zcharia E, Peretz T and Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst. 2004; 96(16):1219-1230.
11. Liu X, Fang H, Chen H, Jiang X, Fang D, Wang Y and Zhu D. An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PloS one. 2012; 7(6):e38659.
12. Liu XY, Tang QS, Chen HC, Jiang XL and Fang H. Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity. Int J Biol Sci. 2013; 9(6):564-577.
13. Murry BP, Blust BE, Singh A, Foster TP and Marchetti D. Heparanase mechanisms of melanoma metastasis to the brain: Development and use of a brain slice model. J Cell Biochem. 2006; 97(2):217-225.
14. Roy M, Reiland J, Murry BP, Chouljenko V, Kousoulas KG and Marchetti D. Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia. 2005; 7(3):253-262.
15. Singh S, Nannuru KC, Sadanandam A, Varney ML and Singh RK. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer. 2009; 100(10):1638-1646.
16. Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R and Singh RK. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res. 2009; 15(7):2380-2386.
17. Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoreto M, Cassinelli G, Lanzi C, Pisano C, Ilan N, Vlodavsky I and Zunino F. Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med. 2011; 15(9):1857-1864.
18. Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N and Elkin M. Significance of heparanase in cancer and inflammation. Cancer Microenviron. 2012; 5(2):115-132.
19. Murry BP, Greiter-Wilke A, Paulsen DP, Hiatt KM, Beltrami CA and Marchetti D. Selective heparanase localization in malignant melanoma. Int J Oncol. 2005; 26(2):345-352.
20. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-6206.
21. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D and Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer. 2016; 53:125-134.
22. Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, Thomson DB, Walpole ET, Haydon AM, Creese BR, Roberts KL, Zalcberg JR and Gonzalez R. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Investigational new drugs. 2008; 26(1):89-94.
23. Arvatz G, Barash U, Nativ O, Ilan N and Vlodavsky I. Posttranscriptional regulation of heparanase gene expression by a 3' AU-rich element. FASEB J. 2011; 24(12):4969-4976.
24. Barash U, Zohar Y, Wildbaum G, Beider K, Nagler A, Karin N, Ilan N and Vlodavsky I. Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia. 2014; 28(11):2178-2187.
25. Boyango I, Barash U, Naroditsky I, Li JP, Hammond E, Ilan N and Vlodavsky I. Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res. 2014; 74:4504-4514.
26. Ramani VC, Vlodavsky I, Ng M, Zhang Y, Barbieri P, Noseda A and Sanderson RD. Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix biology. 2016.
27. Shteingauz A, Boyango I, Naroditsky I, Hammond E, Gruber M, Doweck I, Ilan N and Vlodavsky I. Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy. Cancer Res. 2015; 75(18):3946-3957.
28. Weissmann M, Arvatz G, Horowitz N, Feld S, Naroditsky I, Zhang Y, Ng M, Hammond E, Nevo E, Vlodavsky I and Ilan N. Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. Proc Natl Acad Sci USA. 2016; 113(3):704-709.
29. Bernard D, Mehul B, Delattre C, Simonetti L, Thomas-Collignon A and Schmidt R. Purification and characterization of the endoglycosidase heparanase 1 from human plantar stratum corneum: a key enzyme in epidermal physiology? J Invest Dermatol. 2001; 117(5):1266-1273.
30. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, Metzger S, Sarid R, Naggi A, Casu B, Ilan N, Vlodavsky I and Abramovitch R. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J. 2005; 19(2):211-221.
31. Ohkawa T, Naomoto Y, Takaoka M, Nobuhisa T, Noma K, Motoki T, Murata T, Uetsuka H, Kobayashi M, Shirakawa Y, Yamatsuji T, Matsubara N, Matsuoka J, et al. Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest. 2004; 84(10):1289-1304.
32. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N and Vlodavsky I. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia. 2006; 8(12):1055-1061.
33. Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, Fujiwara T, Gunduz M, Nagatsuka H, Nakajima M, Tanaka N and Haisa M. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest. 2003; 83(5):613-622.
34. McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, Terrett J and Page M. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun. 2000; 276(3):1170-1177.
35. Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, Arvatz G, Naroditsky I, Ilan N, Doweck I and Vlodavsky I. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem. 2010; 285(36):28010-28019.
36. Gross-Cohen M, Feld S, Doweck I, Neufeld G, Hasson P, Arvatz G, Barash U, Naroditsky I, Ilan N and Vlodavsky I. Heparanase 2 attenuates head and neck tumor vascularity and growth. Cancer Res. 2016; 76(9):2791-2801.
37. Gross-Cohen M, Feld S, Naroditsky I, Nativ O, Ilan N and Vlodavsky I. Heparanase 2 expression inversely correlates with bladder carcinoma grade and stage. Oncotarget. 2016; 7(16):22556-22565. doi: 10.18632/oncotarget.8003.
38. Bar-Sela G, Kaplan-Cohen V, Ilan N, Vlodavsky I and Ben-Izhak O. Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology. 2006; 49(2):188-193.